Cannabidiol Fails to Protect Against Cannabis-Induced Symptoms in Schizophrenia
December 14, 2025
A new study examined whether cannabidiol could mitigate the acute a...
Read More
Relapse Criteria in Schizophrenia
December 2, 2025
Relapse prevention is critical in long-term schizophrenia managemen...
Read More
SSRIs and SNRIs Lower Relapse in Clozapine Treated Schizophrenia
September 23, 2025
Clozapine remains the gold standard for treatment-resistant schizop...
Read More
Clozapine Shows Greater Benefit in Schizoaffective Disorder
August 23, 2025
A recent real-world clinical trial found that clozapine appears to ...
Read More
Efficacy and Safety of Brexpiprazole in Adolescents with Schizophrenia
May 25, 2025
A recent study evaluated the short-term efficacy and safety of brex...
Read More
Population Study Reveals Most Effective Antipsychotic Strategies for First-Episode Schizophrenia
February 16, 2025
A recent population-based cohort study examined the effectiveness o...
Read More
Antipsychotic Polypharmacy on the Rise
December 16, 2024
Antipsychotic polypharmacy remains a common practice despite eviden...
Read More
Glutamatergic Modulation for Psychiatric Disorders
November 10, 2024
he science behind the role of glutamatergic neurotransmissions role...
Read More
Positive Results For Lumateperone in the Prevention of Relapse in Adult Patients with Schizophrenia
November 5, 2024
Positive results have been announced from phase III study evaluatin...
Read More
FDA Approves First Muscarinic Agonist for Schizophrenia
September 26, 2024
The U.S. Food and Drug Administration has approved xanomeline-tros...
Read More
Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia
September 14, 2024
A new era of treatment strategies seems to be dawning with an incre...
Read More
Mortality Risk In Long-Acting Injectable Versus Oral Antipsychotics In Schizophrenia
September 9, 2024
Individuals with schizophrenia often struggle with consistently tak...
Read More